Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein
- PMID: 15850385
- DOI: 10.1021/bi0476578
Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein
Abstract
Deletion of insulin-degrading enzyme (IDE) in mice causes accumulation of cerebral amyloid beta-protein (Abeta), hyperinsulinemia, and glucose intolerance. Together with genetic linkage and allelic association of IDE to Alzheimer's disease (AD) and type 2 diabetes mellitus (DM2), these findings suggest that IDE hypofunction could mediate human disease. To date, no coding mutations have been found in the canonical isoform of IDE, suggesting that pathological mutations could exist in undiscovered exons or regulatory regions, including untranslated regions (UTRs). However, neither isoforms arising from alternative splicing nor the UTRs have been described. Here, we systematically characterize human IDE mRNAs, identify a novel splice form, and compare its subcellular distribution, kinetic properties, and ability to degrade Abeta to the known isoform. Six distinct human IDE transcripts were identified, with most of the variance attributable to alternative polyadenylation sites. In the novel spliceoform, an exon we designate "15b" replaces the canonical exon "15a", and the resultant variant is widely expressed. Subcellular fractionation, immunofluorescent confocal microscopy, and immunogold-electron microscopy reveal that the 15b-IDE protein occurs in both cytosol and mitochondria. Organelle targeting of both isoforms is determined by which of two translation start sites is used, and only those isoforms utilizing the second site regulate levels of secreted Abeta. 15b-IDE can exist as a heterodimer with the 15a isoform or as a homodimer. The apparent K(m) values of recombinant 15b-IDE for both insulin and Abeta are significantly higher and the k(cat) and catalytic efficiency markedly lower than those of 15a-IDE. In accord, cells coexpressing beta-amyloid precursor protein (APP) and 15b-IDE accumulated significantly more Abeta in their media than those expressing APP and 15a-IDE. Our results identify a novel, catalytically inefficient form of IDE expressed in brain and non-neural tissues and recommend novel regions of the IDE gene in which to search for mutations predisposing patients to AD and DM2.
Similar articles
-
Somatostatin: a novel substrate and a modulator of insulin-degrading enzyme activity.J Mol Biol. 2009 Feb 6;385(5):1556-67. doi: 10.1016/j.jmb.2008.11.025. Epub 2008 Nov 25. J Mol Biol. 2009. PMID: 19073193
-
Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria.Biochem J. 2004 Nov 1;383(Pt. 3):439-46. doi: 10.1042/BJ20041081. Biochem J. 2004. PMID: 15285718 Free PMC article.
-
Increased expression of Abeta degrading enzyme IDE in the cortex of transgenic mice with Alzheimer's disease-like neuropathology.Neurosci Lett. 2008 Jun 20;438(2):216-20. doi: 10.1016/j.neulet.2008.04.025. Epub 2008 Apr 12. Neurosci Lett. 2008. PMID: 18455870
-
Insulin-degrading enzyme.Clin Invest Med. 1996 Jun;19(3):149-60. Clin Invest Med. 1996. PMID: 8724818 Review.
-
[Cerebral proteolysis of amiloid-b peptide: relevance of insulin-degrading enzyme in Alzheimer's disease].Medicina (B Aires). 2009;69(4):466-72. Medicina (B Aires). 2009. PMID: 19770104 Review. Spanish.
Cited by
-
Inhibition of Insulin Degrading Enzyme to Control Diabetes Mellitus and its Applications on some Other Chronic Disease: a Critical Review.Pharm Res. 2022 Apr;39(4):611-629. doi: 10.1007/s11095-022-03237-7. Epub 2022 Apr 4. Pharm Res. 2022. PMID: 35378698 Review.
-
Effects of Fasting and Feeding on Transcriptional and Posttranscriptional Regulation of Insulin-Degrading Enzyme in Mice.Cells. 2021 Sep 16;10(9):2446. doi: 10.3390/cells10092446. Cells. 2021. PMID: 34572095 Free PMC article.
-
Gain of PITRM1 peptidase in cortical neurons affords protection of mitochondrial and synaptic function in an advanced age mouse model of Alzheimer's disease.Aging Cell. 2021 May;20(5):e13368. doi: 10.1111/acel.13368. Epub 2021 May 5. Aging Cell. 2021. PMID: 33951271 Free PMC article.
-
Hydroxypyridinethione Inhibitors of Human Insulin-Degrading Enzyme.ChemMedChem. 2021 Jun 7;16(11):1775-1787. doi: 10.1002/cmdc.202100111. Epub 2021 Mar 31. ChemMedChem. 2021. PMID: 33686743 Free PMC article.
-
Targeting Insulin-Degrading Enzyme in Insulin Clearance.Int J Mol Sci. 2021 Feb 24;22(5):2235. doi: 10.3390/ijms22052235. Int J Mol Sci. 2021. PMID: 33668109 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous